Geniposide suppresses hepatic glucose production via AMPK in hepG2 cells

Biological and Pharmaceutical Bulletin

Volumn 39, Issue 4, 2016, Pages 484-491

  Guo, Lixia ^a   Zheng, Xuxu ^a   Liu, Jianhui ^a   Yin, Zhongyi ^a  

^a CHONGQING TECHNOLOGY AND BUSINESS UNIVERSITY   (China)

Author keywords

AMP Activated Protein Kinase; Geniposide; Hepatic Glucose Production; HepG2 Cell

Indexed keywords

ACETATE COENZYME A LIGASE; COMPOUND C; GENIPOSIDE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN SERINE THREONINE KINASE INHIBITOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; FOXO1 PROTEIN, HUMAN; IRIDOID;

ANTIDIABETIC ACTIVITY; ARTICLE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GENE SILENCING; GLUCONEOGENESIS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; LIVER METABOLISM; MEDICINAL PLANT; METABOLIC INHIBITION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HEP-G2 CELL LINE; LIVER; METABOLISM;

AMP-ACTIVATED PROTEIN KINASES; CELL SURVIVAL; FORKHEAD BOX PROTEIN O1; GLUCOSE; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; IRIDOIDS; LIVER; RNA, SMALL INTERFERING;

EID: 84964669868     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b15-00591     Document Type: Article

References (36)

1. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J. Clin. Invest., 74, 1238-1246 (1984).
2. Roden M, Petersen KF, Shulman GI. Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Prog. Horm. Res., 56, 219-237 (2001).
3. Consoli A, Nurjhan N, Capani F, Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes, 38, 550-557 (1989).
4. Viollet B, Lantier L, Devin-Leclerc J, Hebrard S, Amouyal C, Mounier R, Foretz M, Andreelli F. Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front. Biosci., 14, 3380-3400 (2009), Landmark Ed.
5. Kim MS, Park JY, Namkoong C, Jang PG, Ryu JW, Song HS, Yun JY, Namgoong IS, Ha J, Park IS, Lee IK, Viollet B, Youn JH, Lee HK, Lee KU. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat. Med., 10, 727-733 (2004).
6. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ, Stuck BJ, Kahn BB. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature, 428, 569-574 (2004).
7. Jørgensen SB, Viollet B, Andreelli F, Frøsig C, Birk JB, Schjerling P, Vaulont S, Richter EA, Wojtaszewski JF. Knockout of the alpha2 but not alpha1 5-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside but not contraction-induced glucose uptake in skeletal muscle. J. Biol. Chem., 279, 1070-1079 (2004).
8. Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, Kahn A, Thorens B, Vaulont S, Viollet B. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes, 54, 1331-1339 (2005).
9. Miyasita S. A historical study of Chinese drugs for the treatment of Jaundice. Am. J. Chin. Med. (Gard City NY), 4, 239-243 (1976).
10. Kim J, Kim HY, Lee SM. Protective effects of geniposide and genipin against hepatic ischemia/reperfusion injury in mice. Biomol. Ther. (Seoul), 21, 132-137 (2013).
11. Cai L, Li R, Tang WJ, Meng G, Hu XY, Wu TN. Antidepressantlike effect of geniposide on chronic unpredictable mild stressinduced depressive rats by regulating the hypothalamus-pituitary- adrenal axis. Eur. Neuropsychopharmacol., 25, 1332-1341 (2015).
12. Zhang Y, Yin F, Liu J, Liu Z, Guo L, Xia Z, Zidichouski J. Geniposide attenuates insulin-deficiency-induced acceleration of betaamyloidosis in an APP/PS1 transgenic model of Alzheimer's disease. Neurochem. Int., 89, 7-16 (2015).
13. Shi Q, Cao J, Fang L, Zhao H, Liu Z, Ran J, Zheng X, Li X, Zhou Y, Ge D, Zhang H, Wang L, Ran Y, Fu J. Geniposide suppresses LPS-induced nitric oxide, PGE2 and inflammatory cytokine by downregulating NF-kappaB, MAPK and AP-1 signaling pathways in macrophages. Int. Immunopharmacol., 20, 298-306 (2014).
14. Gong N, Fan H, Ma AN, Xiao Q, Wang YX. Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors. Neuropharmacology, 84, 31-45 (2014).
15. Guo LX, Liu JH, Yin F. Regulation of insulin secretion by geniposide: possible involvement of phosphatidylinositol 3-phosphate kinase. Eur. Rev. Med. Pharmacol. Sci., 18, 1287-1294 (2014).
16. Liu J, Guo L, Yin F, Zhang Y, Liu Z, Wang Y. Geniposide regulates glucose-stimulated insulin secretion possibly through controlling glucose metabolism in INS-1 cells. PLoS ONE, 8, e78315 (2013).
17. Song X, Guo M, Wang T, Wang W, Cao Y, Zhang N. Geniposide inhibited lipopolysaccharide-induced apoptosis by modulating TLR4 and apoptosis-related factors in mouse mammary glands. Life Sci., 119, 9-17 (2014).
18. Sung YY, Lee AY, Kim HK. The Gardenia jasminoides extract and its constituent, geniposide, elicit anti-allergic effects on atopic dermatitis by inhibiting histamine in vitro and in vivo. J. Ethnopharmacol., 156, 33-40 (2014).
19. Kimura Y, Okuda H, Arichi S. Effects of geniposide isolated from Gardenia jasminoides on metabolic alterations in high sugar dietfed rats. Chem. Pharm. Bull., 30, 4444-4447 (1982).
20. Wu SY, Wang GF, Liu ZQ, Rao JJ, Lu L, Xu W, Wu SG, Zhang JJ. Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Acta Pharmacol. Sin., 30, 202-208 (2009).
21. Yamashita R, Saito T, Satoh S, Aoki K, Kaburagi Y, Sekihara H. Effects of dehydroepiandrosterone on gluconeogenic enzymes and glucose uptake in human hepatoma cell line, HepG2. Endocr. J., 52, 727-733 (2005).
22. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes, 51, 2677-2683 (2002).
23. Cordero-Herrera I, Martin MA, Bravo L, Goya L, Ramos S. Cocoa flavonoids improve insulin signalling and modulate glucose production via AKT and AMPK in HepG2 cells. Mol. Nutr. Food Res., 57, 974-985 (2013).
24. Liu J, Yin F, Zheng X, Jing J, Hu Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem. Int., 51, 361-369 (2007).
25. Guo LX, Xia ZN, Gao X, Yin F, Liu JH. Glucagon-like peptide 1 receptor plays a critical role in geniposide-regulated insulin secretion in INS-1 cells. Acta Pharmacol. Sin., 33, 237-241 (2012).
26. Krssak M, Brehm A, Bernroider E, Anderwald C, Nowotny P, Man CD, Cobelli C, Cline GW, Shulman GI, Waldhäusl W, Roden M. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes, 53, 3048-3056 (2004).
27. Roden M, Bernroider E. Hepatic glucose metabolism in humans- its role in health and disease. Best Pract. Res. Clin. Endocrinol. Metab., 17, 365-383 (2003).
28. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 49, 2063-2069 (2000).
29. Hardie DG. The AMP-activated protein kinase pathway-new players upstream and downstream. J. Cell Sci., 117, 5479-5487 (2004).
30. Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, Hue L, Andreelli F. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J. Physiol., 574, 41-53 (2006).
31. Misra P, Chakrabarti R. The role of AMP kinase in diabetes. Indian J. Med. Res., 125, 389-398 (2007).
32. Yamazaki Y, Kamei Y, Sugita S, Akaike F, Kanai S, Miura S, Hirata Y, Troen BR, Kitamura T, Nishino I, Suganami T, Ezaki O, Ogawa Y. The cathepsin L gene is a direct target of FOXO1 in skeletal muscle. Biochem. J., 427, 171-178 (2010).
33. Nakae J, Cao Y, Oki M, Orba Y, Sawa H, Kiyonari H, Iskandar K, Suga K, Lombes M, Hayashi Y. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes, 57, 563-576 (2008).
34. Nerurkar PV, Nishioka A, Eck PO, Johns LM, Volper E, Nerurkar VR. Regulation of glucose metabolism via hepatic forkhead transcription factor 1 (FoxO1) by Morinda citrifolia (noni) in high-fat diet-induced obese mice. Br. J. Nutr., 108, 218-228 (2012).
35. Xiong X, Tao R, DePinho RA, Dong XC. Deletion of hepaticFoxO1/3/4 genes in mice significantly impacts on glucose metabolism through downregulation of gluconeogenesis and upregulation of glycolysis. PLoS ONE, 8, e74340 (2013).
36. Zhang W, Patil S, Chauhan B, Guo S, Powell DR, Le J, Klotsas A, Matika R, Xiao X, Franks R, Heidenreich KA, Sajan MP, Farese RV, Stolz DB, Tso P, Koo SH, Montminy M, Unterman TG. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J. Biol. Chem., 281, 10105-10117 (2006).